Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2020 07:50 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare...
August 25, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome...
August 10, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020Multiple data readouts for soticlestat expected in Q3 2020,...
August 05, 2020 09:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
July 23, 2020 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics y Angelini Pharma firman un acuerdo exclusivo de licencia para desarrollar, fabricar y comercializar OV101 para el tratamiento del síndrome de Angelman en Europa

Angelini Pharma obtiene derechos exclusivos de desarrollo, fabricación y comercialización de OV101 (gaboxadol) para el tratamiento potencial del síndrome de Angelman en la Unión Europea y otros países...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

オービッド･セラピューティクスとアンジェリーニ･ファーマ、アンジェルマン症候群の治療薬としてのOV101のヨーロッパにおける開発、製造、商品化に関する独占ライセンス契約を締結

アンジェリーニ･ファーマは、EU、欧州経済地域諸国、およびスイス、トルコ、英国、ロシアにおいて、アンジェルマン症候群への治療効果を期待できるOV101 (ガボキサドール) の開発、製造、商品化の独占的な権利を取得オービッド･セラピューティクスは、前払い金の2,000万ドル (約21億4,000万円) に加え、開発、製造、販売のマイルストーンを達成した段階で最大2億1,250万ドル...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics und Angelini Pharma schließen exklusive Lizenzvereinbarung zur Entwicklung, Herstellung und Vermarktung von OV101 zur Behandlung des Angelman-Syndroms in Europa ab

Angelini Pharma erhält Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von OV101 (Gaboxadol) zur potenziellen Behandlung des Angelman-Syndroms in der Europäischen Union und anderen...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics et Angelini Pharma concluent un accord de licence exclusif concernant le développement, la fabrication et la commercialisation d'OV101 pour le traitement du syndrome d'Angelman en Europe

Angelini Pharma obtient les droits exclusifs de développement, de fabrication et de commercialisation d'OV101 (gaboxadol) pour le traitement potentiel du syndrome d'Angelman dans l'Union européenne et...
July 14, 2020 18:01 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics和Angelini Pharma签订开发、生产和商业化独家许可协议以利用OV101在欧洲治疗天使综合征

Angelini Pharma获得OV101（gaboxadol）开发、生产和商业化独家权利，用于欧盟、欧洲经济区其他国家以及瑞士、土耳其、英国和俄罗斯天使综合征患者的潜在治疗 Ovid Therapeutics将获得2000万美元前期付款并将在实现开发、制造和销售里程碑后再获得高达2.125亿美元的付款；此外如成功实现商业化还将获得净销售额两位数百分比的特许权收入 Angelini...